Research into Treatments for Helsmoortel-Van der Aa Syndrome

There is currently no approved treatment for ADNP-related Helsmoortel-Van der Aa syndrome (HVDAS). Several academic research groups are actively investigating potential treatments, offering genuine grounds for hope. At the same time, it is important to be transparent about the current evidence and stage of development of each approach.

So far, only ketamine has been tested in children with HVDAS in a registered clinical trial. A trial with NAP (davunetide) has been announced but has not yet started. All other approaches are still being tested in cells and animals in the laboratory.

This page explains the drug discovery and development process and outlines where research into treatments for HVDAS currently stands, in plain language: what each approach involves, how far it has progressed, and what it could mean for your child.

From the lab to a medicine: how far we have come?

Every new medicine goes through the same steps, and each step takes years to complete. The development of a drug goes through four major steps:

1. Basic research: understand the disease mechanism – see “The Molecular Biology of ADNP”

2. Preclinical development: test efficacy, mode of action, dosing and safety of the drug candidate. Animal models are crucial at this step. Yet they do not necessarily predict clinical benefit in humans.

3. Clinical trials in humans:

Phase I: can it be safely used in humans?

Initial safety, tolerability and dosing. Some candidates fail because of adverse effects or unsuitable drug exposure.

Phase II: does it actually work?

A critical bottleneck. Many drugs fail to show convincing evidence of benefit in patients.

Phase III: does the benefit hold up?

Larger trials may reveal that efficacy is insufficient, safety issues emerge, or the benefit does not justify the risks.

4. Regulatory review and approval. Health authorities review all results before a medicine can be prescribed (for example the EMA in Europe or the FDA in the USA).

Across the full pipeline, only a minority of drug candidates entering clinical testing ultimately gain approval. Many fail in Phase II and III. Lack of sufficient efficacy is generally the leading cause, although safety problems and other issues also contribute.

The deeper problem however is often earlier than Phase II: the biological hypothesis may be wrong, the drug may not affect the intended target sufficiently, or the animal and cellular models may not predict what happens in humans. A 2024 Nature Genetics study found that drugs were less likely to fail in clinical trials when there was stronger genetic evidence supporting their targets (Razuvayevskaya et al., 2024).

No drug candidate for HVDAS has yet been tested in a trial with a comparison (placebo) group, not even at the earliest stage in people, and none is approved.

The options at a glance
Each option explained
1. Ketamine

Ketamine is a well-known medicine, used for example for anesthesia. Researchers chose it because experiments on brain cells from rats suggested that low doses might raise ADNP levels (Brown et al., 2015). Increased ADNP protein levels upon ketamine treatment were also observed in blood cells from people with HVDAS grown in the lab, but mainly at quite high concentrations that would not be considered safe when used to treat patients (D'Incal et al., 2025).

A small study at Mount Sinai in New York (registered as NCT04388774) gave ten children with HVDAS, aged 6 to 12, a single low dose of ketamine through a drip over 40 minutes (Kolevzon et al., 2022):

• Safety: there were no serious side effects observed. The most common ones were being over-excited or unusually cheerful (5 of 10 children), tiredness (4 of 10) and more aggressive behavior (4 of 10).

• Effects: in the week after the dose, parents and doctors reported improvements in social behavior, attention and hyperactivity, repetitive behavior and sensory sensitivity.

• Limits: everyone knew the children were receiving the drug, because there was no comparison group, and the study was small. The authors of the study describe the results as a first step that must be interpreted with caution.

• Blood tests: ketamine caused short-lived changes in gene activity in the blood, mostly related to the immune system, which returned to normal within a day to a week. The expected rise in ADNP was not seen (Buxbaum Grice et al., 2024).

This was a small pilot study, not a formal Phase I trial. It does not show that ketamine is an effective treatment for HVDAS.

The study also taught researchers something important for future trials. It tested objective measures: brain-wave recordings in response to sounds, and eye-tracking that follows where a child looks (Kolevzon et al., 2022). A separate, painless test recorded the brain's response to visual patterns, called a visual evoked potential, in 12 children with HVDAS. Their responses were weaker and slower than in typically developing children and also differed from those of autistic children without a known genetic cause. This makes it a promising measure for future trials (Levy et al., 2026). To know whether a treatment truly helps, trials need measures like these that give the same result each time, alongside what families and doctors observe.

2. NAP (davunetide)

NAP is a very small piece of the ADNP protein itself, eight building blocks long. It was discovered together with the ADNP gene in 1999 (Bassan et al., 1999). It can be given as a nasal spray and reaches the brain this way. In many cell and animal studies of HVDAS, and of other brain conditions, NAP showed protective effects (Gozes, 2020). In earlier clinical trials for other conditions, such as schizophrenia and memory problems in older adults, it was given to more than 560 adults and was found to be safe (Javitt et al., 2012; Gozes et al., 2024). Unlike for ketamine, the mode of action of NAP is not well understood.

NAP has not yet been tested in children with HVDAS. A trial has been announced, but it has not been officially registered so far. Researchers and parent organizations are still working to secure the funding needed to start it.

3. Gene therapy

1. Gene therapy means using genetic tools to treat a condition at its source: the gene itself. Children with HVDAS have one working copy of the ADNP gene and one changed copy [Link to TAB 1 “The Genetics of ADNP”]. In principle, there are several ways to address this:

• Adding a working copy. A healthy copy of the gene is delivered into cells, usually inside a harmless, emptied-out virus that acts as a delivery vehicle.

• Boosting the healthy copy. Tools such as antisense oligonucleotides (ASOs: short, man-made pieces of genetic material) or adapted gene-editing tools could make the healthy copy work harder, so it makes more normal ADNP.

• Correcting or silencing the changed copy. Gene editing (for example CRISPR) could repair the change, or an ASO could reduce the shortened protein. Whether this shortened protein itself causes harm is an active area of research.

Similar approaches are approved for a few other genetic conditions, which shows they can work in principle. For HVDAS, all these ideas are still at an early laboratory stage. Important questions remain open: how to reach enough brain cells, how much ADNP is the right amount, at what age a treatment would need to start, and whether it would be a single treatment or need repeating. Finally, even if approved, a gene therapy for HVDAS will be complex to administer and likely to be extremely expensive.

4. Searching for new medicines

Most conventional medicines are small molecules: the kind of compounds tablets are made of. Two kinds of search are under way to find new such molecules as drug candidates:

• Molecules that boost the healthy copy. A project at Mount Sinai in New York, funded in 2024 by the autism research foundation SFARI, is screening libraries of small molecules that attach to the gene's working message (RNA) and increase how much normal protein is made. Early results showed more ADNP protein from the healthy copy in lab tests. The project aims to find a few lead molecules for further testing, first in human nerve cells grown in the lab (SFARI, 2024).

• Existing medicines used in a new way (repurposing). Scientists are testing medicines already used to treat other conditions to see whether they can correct problems in cells caused by changes in ADNP. If a suitable medicine is found, it could potentially reach patients sooner because much of its safety profile is already known.

Both are pre-clinical drug discovery efforts at the very beginning of the drug development process (see above). Any promising molecule will need to be further developed and optimized and eventually pass through animal studies and clinical trials before it may be approved by the authorities as a treatment for HVDAS.

What families can do now

Waiting for treatments is difficult. While research continues, there are practical ways to support you and your child, and help advance research:

• Keep up supportive care. Speech therapy, physiotherapy, occupational therapy and good medical follow-up remain the foundation of care today.

• Register with ADNP Europe. Being registered means you hear about new research and trials. It also enables researchers to reach families when a trial opens.

Become a member of ADNP Europe

• Always talk to your child's doctor before trying anything new, including products bought online or abroad.

• Ask questions about any trial you are offered: Is it officially registered? Is there a comparison group? What are the risks?

A word of caution

You may come across products or clinics that claim to treat HVDAS. Today, no treatment has been proven to work for this condition. Medicines tested in research, such as ketamine or NAP, should only be given within an official clinical trial, where safety is closely watched. A trial that is registered (for example on clinicaltrials.gov or in the EU Clinical Trials Register) is public, so its plan can be checked. A proper trial is also approved by an ethics committee before it starts.

Research moves step by step, but it is moving. Interest in ADNP is growing, more research groups are joining, and every family that takes part helps bring better treatments closer.

Key words

© 2025. All rights reserved.